---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: ADX-324-101"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: ADX-324-101. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 81 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence/adx-324-101"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: ADX-324-101

<a id="heading-3.1.2"></a>

## 3.1.2 ADX-324-101

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Registry objective: Part A and Part B

> “The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with Hereditary Angioedema (HAE).”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.1-2"></a>

#### Part A: primary objective at first dosing

> “The primary objective of the study is to evaluate the safety and tolerability of ADX-324 when administered by subcutaneous injection.”

Source: [ADARx Pharmaceuticals (2023)](https://www.adarx.com/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324/)

<a id="topic-3.1.2.1-3"></a>

#### Part A and Part B: objectives in the quarterly report

> “Our Phase 1/2 clinical trial evaluated the safety and tolerability, PK activity and PD activity of onvuzosiran in healthy volunteers and HAE patients.”

Source: [ADARx Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458444/adrx-20260930.htm)

<a id="topic-3.1.2.1-4"></a>

#### Part B: secondary objective and exploratory efficacy endpoints

> “The Phase 2a portion evaluated the safety and tolerability, pharmacokinetic (PK) activity and pharmacodynamic (PD) activity of onvuzosiran in HAE patients.”
> “with a secondary objective of PK activity and PD activity.”
> “Exploratory endpoints also included several measures of efficacy, including among other things, the reduction in the rate of HAE attacks, HAE attacks requiring treatment and HAE quality of life.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Registry site, dates, and status

| Field | Reported value |
| --- | --- |
| Location | “Adelaide, South Australia, Australia, 5000 CMAX Clinical Research” |
| Study start | “Study Start (Actual) 2022-12-14” |
| Primary completion | “Primary Completion (Estimated) 2027-12-31” |
| Study completion | “Study Completion (Estimated) 2027-12-31” |
| Status | “Active, not recruiting” |

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.2-2"></a>

#### Part A: country at first dosing

> “The study is being conducted in Australia”

Source: [ADARx Pharmaceuticals (2023)](https://www.adarx.com/adarx-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-clinical-study-of-adx-324/)

<a id="topic-3.1.2.2-3"></a>

#### Part B: start date

> “In January 2024, we initiated our Phase 2a clinical trial of SC doses of onvuzosiran in patients with HAE.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.2-4"></a>

#### Part A interim analysis: follow-up at the time of analysis

> “The interim analysis from blinded data includes observations up to 155 days post-dose; participants will be observed up to 12 months.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-3.1.2.2-5"></a>

#### Part A and Part B: data cutoff of the workshop abstract

> “Results are shared here from data-cut as of December 5th, 2024.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.2-6"></a>

#### Part A and Part B: data dates of the AAAAI poster figures

> “Draft data as of Dec 4, 2024”
> “Draft data as of April 2025”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.2-7"></a>

#### Part B: safety and efficacy data cutoffs in the prospectus

> “Onvuzosiran has been generally well-tolerated in both healthy volunteers and in HAE patients as of the August 5, 2026 safety data cutoff date, with no treatment-related SAEs.”
> “with one patient remaining attack-free for 18 consecutive months on Q6M dosing as of the August 19, 2026 data cutoff date, after one mild attack on Day 153.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.2-8"></a>

#### Part B: data cutoff of the November 2026 presentation

> “Interim data as of the November 5, 2026 cutoff date”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Registry official title

> “A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study in Healthy Volunteers and a Phase 2a, Open-Label Study in Patients With Hereditary Angioedema to Evaluate the Safety, Tolerability, PK and PD of ADX-324”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.3-2"></a>

#### Registry design: two parts

> “The clinical study described in this protocol is a Phase 1, single-center study evaluating safety, tolerability, PK, and PD of ADX-324.”
> “Randomized, double-blind, placebo-controlled, parallel group, single ascending dose (SAD) in HV with up to 6 dose cohorts.”
> “Expansion cohort in participants with Hereditary Angioedema (HAE) at selected dose from Part A and will be open label.”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.3-3"></a>

#### Part A: randomization ratio and sentinel dosing

> “For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo).”
> “Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed.”
> “The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.3-4"></a>

#### Part A: cohorts as described in the prospectus

> “We conducted a Phase 1, randomized, placebo-controlled, double-blind clinical trial in healthy volunteers, where participants were administered single ascending, SC doses of onvuzosiran, ranging from 0.4 to 6 mg/kg across seven cohorts.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.3-5"></a>

#### Part A and Part B: cohorts as described in the workshop abstract

> “A Phase 1, healthy volunteer placebo-controlled single dose escalation study of ADX-324 in 6 cohorts (0.4 mg/kg to 6 mg/kg) and 1 cohort administered 2 doses of 140 mg ADX-324 or placebo 3 months apart, and an open-label Phase 2a study in HAE patients with ADX-324 administered SC every 6 months was conducted”
> “in a phase 2a, dose range finding study”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.3-6"></a>

#### Part A and Part B: cohorts as described in the EAACI abstract

> “A Phase 1, randomized, placebo-controlled, single–ascending-dose trial of subcutaneous (SC) onvuzosiran (0.4 mg/kg to 6 mg/kg) was conducted in healthy adults across 5 doses with an additional group of repeat-dosing every 3 months.”
> “An open-label Phase 2 study of 245 mg every 6 months in HAE patients is completing follow-up.”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

<a id="topic-3.1.2.3-7"></a>

#### Part A interim: planned dose escalation and planned HAE study

> “A double-blind, first-in-human Phase 1 study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ADX-324 in healthy volunteers (HVs) following a single subcutaneous dose (NCT05691361).”
> “The study continues, dose-escalating ADX-324 for 2 mandatory (4 and 8 mg/kg) and one optional (up to 12 mg/kg) cohorts in HVs.”
> “An open-label, single-dose study in HAE patients is planned.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-3.1.2.3-8"></a>

#### Part B: continued dosing after the objectives were assessed

> “While patients continue to be dosed, given the reduction in HAE attack rate observed as of the August 19, 2026 data cutoff date, we believe sufficient safety, PK data and PD data have been collected to assess the primary and secondary objectives.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Part A: inclusion criteria for healthy volunteers

> “Male and female adults 18 to 55 years old”
> “Body mass index (BMI) between 18 and 30 kg/m2”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.4-2"></a>

#### Part A: selected exclusion criteria for healthy volunteers

> “History of liver disease, Gilbert's syndrome, or abnormal liver function test”
> “Estimated creatinine clearance <60 mL/min or serum creatinine > 1.5-fold upper limit of normal.”
> “Use of any prescription, vaccines, supplements/vitamins, or over-the counter medication”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.4-3"></a>

#### Part B: inclusion criteria for participants with HAE

> “Male and female ≥18 years old, inclusive, at the time of signing the PICF”
> “Confirmed diagnosis of HAE Types I or II”
> “Evidence of an average of (at least) one HAE attack per month”
> “Participants must have access to, and the ability to use, acute medication(s) to treat angioedema attacks.”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.4-4"></a>

#### Part B: selected exclusion criteria for participants with HAE

> “Concurrent diagnosis of any other type of chronic angioedema”
> “History of clinically significant arterial or venous thrombosis, or current history of a clinically significant prothrombotic risk.”
> “Use of C1-INH products, androgens, antifibrinolytics or other small molecule medications for routine prophylaxis within four half-lives prior to screening”
> “Treatment with another investigational product or biologic agent within 30 days prior to the study drug administration”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Registry interventions

| Intervention | Description |
| --- | --- |
| ADX-324 | “siRNA duplex oligonucleotide” |
| Placebo | “saline” |

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.5-2"></a>

#### Part B: starting dose selection

> “This will be initiated at the dose level determined by the Safety Review Committee from SAD in HVs.”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.5-3"></a>

#### Part A: weight-based cohorts in the pharmacokinetic figure

| Cohort | Dose as printed |
| --- | --- |
| Phase 1 cohort 1 | “Phase 1 Cohort 1 (0.4 mg/mkg)” |
| Phase 1 cohort 2 | “Phase 1 Cohort 2 (1.0 mg/mkg)” |
| Phase 1 cohort 3 | “Phase 1 Cohort 3 (2.0 mg/mkg)” |
| Phase 1 cohort 4 | “Phase 1 Cohort 4 (4.0 mg/mkg)” |
| Phase 1 cohort 5 | “Phase 1 Cohort 5 (6.0 mg/mkg)” |
| Phase 2 cohort 1 | “Phase 2 Cohort 1 (2.0 mg/mkg)” |

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.5-4"></a>

#### Part A: repeat-dose cohort

> “one cohort received two 140 mg doses 3 months apart”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.5-5"></a>

#### Part B: doses and dosing interval

> “Phase 2a doses: 122.5 mg Q6M, or 245 mg Q6M”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.5-6"></a>

#### Part B: doses as stated in the AAAAI abstract

> “An ongoing open-label Phase 2 study in HAE patients involves SC ADX-324 dosing Q6M.”
> “In Phase 2, one patient received 122.5 mg and two patients received 245 mg.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

<a id="topic-3.1.2.5-7"></a>

#### Part B: doses as stated in the workshop abstract

> “Three HAE patients have been dosed with ADX-324 at 2 mg/kg (n = 1, approximately 125 mg) and 245 mg (n = 2).”
> “one HAE patient was dosed at 122 mg and two patients were dosed at 245 mg.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.5-8"></a>

#### Part B: doses as stated in the EAACI poster

> “Open-label Phase 2 study of 245 mg or 122 mg every 6 months in HAE patients is completing follow-up”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-3.1.2.5-9"></a>

#### Part B: doses compared with the phase 3 regimens

> “Phase 2a: Dosed at Q6M, all were doses either significantly lower than in Phase 3 or less frequent (Phase 3 dose cohorts: 300 mg Q6M or 240 mg Q3M)”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Adverse Event Incidence as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Registry primary outcome measures

> “To evaluate the safety and tolerability of ADX-324 in HVs by incidence, relationship, and severity of adverse events and serious adverse events”
> “To evaluate the safety and tolerability of ADX-324 in HVs by change in baseline electrocardiogram (ECG) parameters (PR, QRS, QT, and QTcF intervals)”
> “To evaluate the safety and tolerability of ADX-324 in HAE by incidence, relationship, and severity of adverse events and serious adverse events”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.6.1-2"></a>

##### Registry secondary outcome measures: prekallikrein and kallikrein

> “To characterize the PD of ADX-324 in HVs by the Change from base in plasma concentrations over time of pre Kallikrein (PKK)”
> “To characterize the PD of ADX-324 in HVs by the Change from base in plasma concentrations over time of Kallikrein (KK)”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.6.1-3"></a>

##### Part B: prekallikrein-kallikrein reduction as a predictor of attacks

> “The patients’ data also supports that PKK-KK response can be used to predict HAE attacks and PKK-KK reductions > 70% are likely to prevent HAE attacks.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.6.1-4"></a>

##### Part B: suppression threshold proposed for an attack-free state

> “We also correlated the episodes of attack with the PKK levels and found that no attacks occurred when the PKK suppression was >80%, suggesting that >80% suppression is potentially needed to achieve a maximal attack-free state.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.6.1-5"></a>

##### Same target: prekallikrein concentration and attack rate with donidalorsen

> “These reductions in HAE attack rates were associated with corresponding reductions in mean plasma prekallikrein trough concentrations of 73% in the donidalorsen Q4W group and 47% in the donidalorsen Q8W group.”
> “Reductions in predicted prekallikrein concentrations were correlated with reductions in predicted HAE attack rates”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12597964/)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Registry planned enrollment

> “Enrollment (Estimated) 53”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.7.1-2"></a>

##### Part A: participants in the prospectus

> “Thirty-eight of 49 healthy volunteers were administered onvuzosiran and the remaining 11 received placebo.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.7.1-3"></a>

##### Part A: participants in the AAAAI poster

> “38 dosed, 11 placebo (total 49)”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.7.1-4"></a>

##### Part A and Part B: participants in the February 2026 release

> “The Phase 1 placebo-controlled single-dose escalation study was conducted in 43 healthy participants who received onvuzosiran (n=32) in 5 cohorts from 0.4 mg/kg to 6 mg/kg or placebo (n=11)”
> “The open-label Phase 2a part of the study is evaluating plasma kallikrein levels and safety with subcutaneous dosing of onvuzosiran every six months in patients with HAE (n=3).”

Source: [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/)

<a id="topic-3.1.2.7.1-5"></a>

##### Part A interim: participants per cohort

> “Four dose cohorts are assessed to date. In each cohort, 6 participants received ADX-324, and 2 received placebo.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-3.1.2.7.1-6"></a>

##### Part A: participants by total dose group in the pharmacodynamic figure

| Total dose group | Group as printed |
| --- | --- |
| Placebo | “ph1, 0 mg (n=11)” |
| Above 0 to 100 mg | “ph1, >0-100 mg (n=13)” |
| Above 100 to 200 mg | “ph1, >100-200 mg (n=8)” |
| Above 200 to 250 mg | “ph1, >200-250 mg (n=6)” |
| Above 250 to 300 mg | “ph1, >250-300 mg (n=3)” |
| Above 300 to 350 mg | “ph1, >300-350 mg (n=4)” |
| Above 350 mg | “ph1, >350 mg (n=4)” |
| 300 mg plus or minus 25 mg | “ADX-324 300 mg +/- 25 mg (n=5)” |

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.7.1-7"></a>

##### Part B: participants enrolled

> “The clinical trial enrolled three patients.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Part A: analysis by total fixed dose

> “When analyzed by total fixed dose, we observed in healthy volunteers that following a single 300 mg +/- 25 mg achieved comparable performance”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.7.2-2"></a>

##### Part A: summary statistic for prekallikrein-kallikrein reduction

> “A single SC injection of ADX-324 of 300 mg (± 25 mg) achieved a mean (SEM) PKK-KK reduction from baseline of > 90% at nadir”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.7.2-3"></a>

##### Part A and Part B: duration of assessments

> “PKK levels and safety assessments were performed for up to 1 year in Phase 1 and are ongoing in Phase 2a.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.7.2-4"></a>

##### Part B: longest follow-up in the AAAAI abstract

> “Plasma PKK-KK protein levels and safety were assessed through Day 445, the longest follow-up.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

<a id="topic-3.1.2.7.2-5"></a>

##### Part B: attack-free interval measured from approximate full inhibition

> “One known feature of siRNA therapeutic candidates such as onvuzosiran is lag time of about 22 days between initial treatment and full inhibition.”
> “The first dotted vertical line (green) indicates the approximate time of full inhibition, while the second dotted vertical line represents 3 months after the first dose.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Registry recruitment status and results posting

> “Active, not recruiting No longer looking for participants”
> “No Results Posted”

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361)

<a id="topic-3.1.2.8.1-2"></a>

##### Part A: completion and withdrawals

> “In the completed Phase 1 portion of our ongoing Phase 1/2 clinical trial”
> “Onvuzosiran was generally well-tolerated and no participants experienced serious adverse events or adverse events that led to study withdrawal.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.1-3"></a>

##### Part B: participants followed and one withdrawal

> “Two patients are still being followed, and one patient withdrew due to administrative reasons.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.1-4"></a>

##### Part A and Part B: discontinuations due to adverse events

> “There was no discontinuations of therapy due to drugs effects.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

> “No related SAEs or withdrawal due to AEs were reported.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Part A interim: prekallikrein nadir by weight-based dose

> “Mean nadir PKK levels were 39% (n=6), 14% (n=6), and 20% (n=5) of baseline following single doses of 0.4, 1.0, and 2.0 mg/kg, respectively.”
> “Cohort 2 PKK mean level remains 21% 99 days post-dose.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-3.1.2.8.3-2"></a>

##### Part A: dose dependence of prekallikrein-kallikrein reduction

> “In the placebo-controlled single dose escalation study of ADX-324, a strong dose-dependent PKK-KK reduction was observed.”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.8.3-3"></a>

##### Part A: 6 mg/kg cohort, reduction at nadir and at 6 months

> “In the completed Phase 1 portion of our ongoing Phase 1/2 clinical trial, we observed at the 6 mg/kg dose level that a single injection reduced circulating PKK/KK levels by a mean of 94% (88% to 97%, median 96%) at nadir and maintained 84% mean suppression (78% to 92%, median 82%) at 6 months.”
> “Three of the four participants at this dose level reached below LLOQ for PKK/KK levels at nadir.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.3-4"></a>

##### Part A: 300 mg plus or minus 25 mg, reduction at nadir and at Day 169 in the prospectus

> “exceeding 90% mean reduction (84% to 96%, median 95%) at nadir with at least 80% mean suppression (65% to 90%, median 83%) sustained through the six-month timepoint (Day 169, as defined in our Phase 3 STOP-HAE trial)”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.3-5"></a>

##### Part A: 6 mg/kg cohort in the November 2026 presentation

> “At the 6 mg/kg dose level, we observed that a single SC injection reduced circulating PKK/KK levels by a mean of 94% at nadir and maintained 84% mean suppression at 6 months”
> “Three of the four participants reached below LLOQ”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-3.1.2.8.3-6"></a>

##### Part A: 300 mg figures as attributed in the November 2026 presentation

> “Phase 1 support: 94% mean (88-97%) reduction at nadir, 84% mean (78-92%) reduction at 6mo at 300 mg +/-25 mg Q6M”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-3.1.2.8.3-7"></a>

##### Part A: 300 mg plus or minus 25 mg in the AAAAI poster

> “In Phase 1, a single SC injection of ADX-324 at 300 mg (±25 mg) achieved a mean PKK-KK reduction from baseline of over 90% at nadir, with >80% reduction maintained through Day 169.”
> “In HV, the 300 mg dose, not a lower one, achieved a 93% mean PKK-KK reduction at nadir and an 80% mean reduction at 6 month”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.8.3-8"></a>

##### Part A: 300 mg dose in the February 2026 release

> “The 300 mg dose showed a 93% reduction at the lowest point, with 80% reduction maintained through Day 169.”

Source: [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/)

<a id="topic-3.1.2.8.3-9"></a>

##### Part A: 300 mg plus or minus 25 mg in the workshop abstract

> “A single SC injection of ADX-324 of 300 mg (± 25 mg) achieved a mean (SEM) PKK-KK reduction from baseline of > 90% at nadir, and > 80% reduction % maintained out to Day 169 (Week 25)”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.8.3-10"></a>

##### Part A: 300 mg dose in the EAACI abstract

> “In Phase 1, a single SC dose of 300 mg reduced plasma kallikrein levels to over 90% at nadir, with maintenance of 80% reduction through Week 25.”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

<a id="topic-3.1.2.8.3-11"></a>

##### Part A: 300 mg dose in the ACAAI abstract

> “In Phase I, a single SC dose of 300 mg reduced plasma kallikrein levels to over 90% at nadir, with maintenance of 80% reduction through Week 25.”

Source: [Riedl et al. (2026b)](https://www.annallergy.org/article/S1081-1206%2826%2900563-6/fulltext)

<a id="topic-3.1.2.8.3-12"></a>

##### Part B: prekallikrein-kallikrein reduction compared with healthy volunteers at similar doses

> “Their PKK-KK reductions mirrored those observed in healthy subjects dosed with ADX-324 at similar levels, supporting the Phase 3 target >80% PKK-KK reduction throughout 6 months in HAE patients at the 300 mg dose.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

> “HAE (122.5 mg, n=1)”
> “HV (122.5 mg +/- 20 mg, n=7)”
> “% PKK-KK reduction from baseline in HV and HAE patients were similar at similar doses.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

> “The PD results showed similar PKK inhibition between healthy volunteers in the Phase 1 clinical trial and HAE patients.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.3-13"></a>

##### Part B: attack-free period after the first dose, August 2026 cutoff

> “Despite dosing at levels below or less frequent than those utilized in our ongoing Phase 3 STOP-HAE clinical trial”
> “all participants in the Phase 2a cohort remained attack-free for 3 months following the initial dose, with one patient remaining attack-free for 18 consecutive months on Q6M dosing as of the August 19, 2026 cutoff date, after one mild attack on Day 153.”
> “During the follow-up, with repeated treatments, the attack-free interval appears to extend over time.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.3-14"></a>

##### Part B: attack-free period after the first dose, November 2026 cutoff

> “All three patients (3/3) were attack-free for 3 months after the initial dose”
> “Patient 202 (245mg, Q6M) remained attack-free for a consecutive 21 months after one mild attack at Day 153”
> “Observed 100% Q3M attack-free rate in Phase 2a after the first dose”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-3.1.2.8.3-15"></a>

##### Part B: attacks in relation to prekallikrein-kallikrein reduction

> “No attacks observed when PKK & KK reduction >80%”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

> “Notably, Phase 2 patients with >80% PKK-KK reductions experienced no HAE attacks, further supporting the potential of 300 mg Q6M to improve attack-free rates.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

> “Notably, HAE patients experienced no attacks when kallikrein levels were reduced by 80%, further supporting the potential of twice-yearly dosing to achieve high attack-free rates.”

Source: [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/)

> “Notably, patients who had plasma kallikrein reduction of >80% were attack-free, supporting 300 mg Q6M dosing.”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

> “Notably, patients who had plasma kallikrein reduction of >80% were attack-free, supporting 300 mg Q6M dosing.”

Source: [Riedl et al. (2026b)](https://www.annallergy.org/article/S1081-1206%2826%2900563-6/fulltext)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Part A interim: severity and most frequent adverse event

> “ADX-324 was safe and well tolerated; no serious adverse events (SAEs) were reported.”
> “All study drug-related AEs were mild except one moderate.”
> “The most frequent AE was headache.”

Source: [Smith et al. (2023)](https://www.annallergy.org/article/S1081-1206%2823%2900702-0/fulltext)

<a id="topic-3.1.2.8.5-2"></a>

##### Part A: most common adverse events and laboratory changes

> “The most common adverse events observed in participants dosed with onvuzosiran included injection site reactions, headache, laboratory changes in blood creatinine phosphokinase (CK) and increases in liver function test (ALT/AST).”
> “All cases of laboratory changes were asymptomatic, transient, and resolved without treatment within a short period of time.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.5-3"></a>

##### Part A: headache and injection-site reaction frequency

> “ADX-324 was well-tolerated with headache and injection-site reaction being the most common AEs in Phase 1 portion (28.9%).”

Source: [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/)

<a id="topic-3.1.2.8.5-4"></a>

##### Part A: serious adverse events by dose in the November 2026 presentation

> “Well-tolerated with doses up to 6.0 mg/kg, no treatment-related SAEs”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-3.1.2.8.5-5"></a>

##### Part B: safety through the August 2026 cutoff

> “Onvuzosiran has been generally well-tolerated, consistent with the safety results observed in Phase 1, with no treatment-related SAEs reported in subjects dosed with onvuzosiran as of the August 5, 2026 safety data cutoff date.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-3.1.2.8.5-6"></a>

##### Part B: safety through the November 2026 cutoff

> “Generally well-tolerated, consistent with the safety results observed in Phase 1, with no SAEs reported in participants dosed with onvuzosiran”

Source: [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0)

<a id="topic-3.1.2.8.5-7"></a>

##### Part A and Part B: serious adverse events and repeat dosing in the AAAAI poster

> “No Serious Adverse Events (SAE’s) were reported in 38 healthy volunteer phase 1 participants and 3 phase 2 HAE patients.”
> “Repeat dosing at 6-month intervals in phase 2 HAE patients was not associated with any safety signal.”
> “Ph1 study showed no drug-related serious adverse events”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-3.1.2.8.5-8"></a>

##### Part A and Part B: serious adverse events in the EAACI poster

> “In 49 healthy volunteer phase 1 participants and 3 phase 2 HAE patients, no Serious Adverse Events (SAEs) were reported in patients treated with onvuzosiran”

Source: [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-3.1.2.8.5-9"></a>

##### Part A and Part B: tolerability in the February 2026 release

> “In the Phase 1/2 study, onvuzosiran was well tolerated, and no serious adverse events were reported, nor were there any treatment-related discontinuations.”

Source: [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/)

<a id="topic-3.1.2.8.5-10"></a>

##### Part A and Part B: tolerability in the congress abstracts

> “ADX-324 was well tolerated in Phase 1 and 2.”

Source: [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095)

> “Phase 1 and 2 studies showed the drug to be well-tolerated.”

Source: [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf)

> “Phase 1 and 2 studies showed onvuzosiran to be well-tolerated.”

Source: [Riedl et al. (2026b)](https://www.annallergy.org/article/S1081-1206%2826%2900563-6/fulltext)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

Part A enrolled healthy volunteers aged 18 to 55 years with a body mass index of 18 to 30 kg/m2, so its pharmacodynamic and safety findings come from a population without HAE. Its dose groups were small: the AAAAI poster lists 3 to 13 participants per total dose group, 5 participants in the 300 mg plus or minus 25 mg group, and the prospectus reports the 6 mg/kg results for 4 participants, 3 of whom were below LLOQ at nadir.

Part B was open-label and uncontrolled and enrolled 3 participants, one of whom withdrew for administrative reasons. Its doses (122.5 mg or 245 mg every 6 months) differ from the phase 3 regimens of 300 mg every 6 months and 240 mg every 3 months. All phase 2a dosing was every 6 months, and the November 2026 presentation describes the 3-month attack-free result as an “Observed 100% Q3M attack-free rate in Phase 2a after the first dose”.

No baseline characteristics, baseline attack rates, on-treatment attack rates, or quality-of-life results were identified. Efficacy is reported as attack-free intervals of individual participants and as an association between attacks and the degree of prekallikrein-kallikrein reduction, and the prospectus figure marks the approximate time of full inhibition (about Day 22) and the point 3 months after the first dose. The proposed threshold differs between documents: “> 70%” in the workshop abstract and “>80%” in the prospectus and other sponsor documents.

The results are available only in congress abstracts, posters, press releases, a corporate presentation, and SEC filings. No peer-reviewed full article was identified, the registry record shows “No Results Posted”, and primary completion is estimated for 2027-12-31. The documents use data cutoffs from December 2024 to November 2026.

The documents report different numbers for Part A: 43 participants (32 onvuzosiran, 11 placebo) in 5 cohorts in the February 2026 release; 49 participants (38 onvuzosiran, 11 placebo) in the posters and the prospectus; and 5, 6, or 7 cohorts in different documents. The prospectus attributes the 94% nadir and 84% six-month reductions to the 6 mg/kg cohort, while the November 2026 presentation attributes them to 6 mg/kg on one page and to 300 mg plus or minus 25 mg on another. The first Part B dose is written as 122 mg, 122.5 mg, or approximately 125 mg.

Safety reporting gives one frequency, 28.9%, attached to headache and injection-site reaction in Part A, and no counts for creatine phosphokinase changes or liver enzyme increases. Serious adverse events are described variously as absent, absent when treatment-related, or absent when drug-related. No immunogenicity data and no electrocardiogram results were identified, although electrocardiogram change is a registry primary outcome.

Source: [ClinicalTrials.gov NCT05691361](https://clinicaltrials.gov/study/NCT05691361); [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm); [ADARx Pharmaceuticals presentation (2026)](https://investors.adarx.com/static-files/fa3237f0-959a-4eec-bd69-918d384722d0); [ADARx Pharmaceuticals onvuzosiran data announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-presents-onvuzosiran-data-supporting-potential-for-sustained-attack-free-rates-with-reduced-treatment-burden-in-patients-with-hae/); [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf); [Murai et al. (2026)](https://doi.org/10.1016/j.jaci.2025.12.095); [Datta et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13685066/); [Cancian et al. (2026a)](https://www.adarx.com/wp-content/uploads/2026/06/EAACI-2026_Cancian-et-al-abstract-vF.pdf); [Cancian et al. (2026b)](https://www.adarx.com/wp-content/uploads/2026/06/Onvuzosiran-Provides-Deep-and-Sustained-Reduction-of-Plasma-Kallikrein-Levels-for-the-Treatment-of-HAE.pdf)

<a id="topic-3.1.2.9-2"></a>

#### Interim and early-phase results: sponsor statement

> “The results from clinical trials or preclinical studies of a therapeutic candidate may not predict the results of later clinical trials of the therapeutic candidate, and interim, topline, or preliminary results of a clinical trial are not necessarily indicative of final results.”

Source: [ADARx Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458444/adrx-20260930.htm)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
